Mytolac (Lanreotide Acetate)

Lanreotide acetate is a synthetic analogue of somatostatin. It binds to somatostatin receptors, mainly SSTR2 and SSTR5, on pituitary and neuroendocrine cells, inhibiting the release of growth hormone and other peptide hormones, thereby reducing disease activity.

The dose of Mytolac is determined by the prescribing clinician based on the patient’s condition, disease severity, and response to therapy. Specific dosing regimens are outlined in the product’s prescribing information and should not be altered without medical guidance.

Safety data for lanreotide acetate in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Mytolac product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mytolac (lanreotide acetate) offers a long‑acting formulation that can be administered subcutaneously every 4‑8 weeks, providing convenient dosing compared with some alternatives that require more frequent injections. Its efficacy in controlling growth hormone and tumour‑related hormone secretion is comparable to other agents in the same class.

Mytolac should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability.

Mytolac is given as a subcutaneous injection, typically by a healthcare professional. The injection site is usually the abdomen or thigh, and the specific administration schedule is defined by the prescribing physician.

Serious adverse events include gallstone formation, pancreatitis, severe allergic reactions, and cardiac arrhythmias. Patients should be monitored for signs of abdominal pain, jaundice, allergic symptoms, or irregular heartbeats, and any concerning signs should prompt immediate medical evaluation.

Mytolac is contraindicated in patients with known hypersensitivity to lanreotide acetate or any of the excipients. Caution is advised for individuals with severe hepatic or renal impairment, uncontrolled diabetes, or a history of gallbladder disease, and the drug should be avoided in these contexts unless benefits outweigh risks.